Prophylactic managements of hepatitis B viral infection in liver transplantation

Table 2 Main results of published studies using vaccination after liver transplantation

Ref.	Patients (n)	Age, median (yr)	HBV-DNA negative before LT	Duration between LT and vaccination	Momo immunosuppression	Response to vaccination1	Vaccination protocol(dose:μg)
Sánchez-Fueyo et al[59], 2000	22	39	100%	33%	63.5	22.7%	40 im/40 im
							3 + 3 (/cycle)
							without HBIG
Angelico et al[60], 2002	17	53	100%	48%	100	11.8%	40 im/10 sc/40 im
							3 + 6 + 3 (/cycle)
							without HBIG
Bienzle et al[63], 2003	20	54	100%	78%	80	80%	20 im or 100 im
							5 + 3 (/cycle)
							with HBIG Adjuvant: MPL + QS21
Stärkel et al[64], 2005	10	49	90%	55%	100	40%	40 im/40 im
							5 (/cycle)
							with HBIG
							Adjuvant: MPL
Lo et al[66], 2005	52	47	81%	14%	92.3	1.9%	40 im
							3 + 3 (/cycle)
							without HBIG
Rosenau et al[62], 2006	8	50	37.5%	60%	37.5	12.5%	20 im
							6 (/cycle)
							without HBIG
Lo et al[66], 2007	20	52	80%	21%	85	35%	HBs + preS 20 im
							3 + 3 (/cycle)
							without HBIG
Tahara et al[69], 2009	20	53	75%	20%	60	65%	20 im or 40 im
							unrestraint
							with HBIG
							under immune-monitoring
Di Paolo et al[65], 2010	18	59	100%	73%	89	44%	20 im
							6 + 6 (/cycle)
							HBIG withdraw
							Adjuvant: MPL

¹Anti-HBsAb level ≥ 100 IU/L. HBV: Hepatitis B virus; MPL: Monophosphoryl lipid A; HBIG: Hepatitis B immunoglobulin; QS21: Quillaja saponaria Molina; HBsAb: Hepatitis B surface antibody; LT: Liver transplantation; im: Intra-muscular administration; sc: Subcutaneous administration.